Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision

Xie, Daxing; Wang, Y; Shen, Jie; Hu, Jia; Yin, Ping; Gong, Jianping

doi:10.1002/bjs.10881

Cited by 21 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further to Nilsson et al . 's letter following the publication of a single‐centre trial evaluating the impact of complete mesogastric excision (CMG) in reducing free intraperitoneal cancer cells and prognosis, I must respond by saying that some insights are conceptualized.…”

mentioning

confidence: 99%

Correspondence

2019

British Journal of Surgery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Correspondence

2019

British Journal of Surgery

View full text Add to dashboard Cite

“…CEA expression level after gastrectomy was lower in the group with complete mesogastric excision. In patients with low CEA expression before gastrectomy, D2 gastrectomy with complete mesogastric excision was associated with better disease-free survival [ 175 ].…”

Section: Diagnostic and Potential Target Biomarkersmentioning

confidence: 99%

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Niclauss

Gütgemann

Dohmen

et al. 2021

Cancers

View full text Add to dashboard Cite

Overall survival of gastric cancer remains low, as patients are often diagnosed with advanced stage disease. In this review, we give an overview of current research on biomarkers in gastric cancer and their implementation in treatment strategies. The HER2-targeting trastuzumab is the first molecular targeted agent approved for gastric cancer treatment. Other promising biomarkers for targeted therapies that have shown relevance in clinical trials are VEGF and Claudin 18.2. Expression of MET has been shown to be a negative prognostic factor in gastric cancer. Targeting the PD-1/PD-L1 pathway with immune checkpoint inhibitors has proven efficacy in advanced gastric cancer. Recent technology advances allow the detection of circulating tumor cells that may be used as diagnostic and prognostic indicators and for therapy monitoring in gastric cancer patients. Prognostic molecular subtypes of gastric cancer have been identified using genomic data. In addition, transcriptome profiling has allowed a comprehensive characterization of the immune and stromal microenvironment in gastric cancer and development of novel risk scores. These prognostic and predictive markers highlight the rapidly evolving field of research in gastric cancer, promising improved treatment stratification and identification of molecular targets for individualized treatment in gastric cancer.

show abstract

“…The standard procedure of laparoscopic gastrectomy with D2 lymph node dissection in our institution was summarized and published previously. 22,23 In brief, left gastroepiploic vessels (LGEVs), right gastroepiploic vessels (RGEVs), left gastric vein and artery, right gastric vessels (RGVs) were dissected, exposed, and ligated. D2 dissection of lymph node stations were performed according to Japanese Gastric Cancer Treatment Guidelines.…”

Section: Surgical Procedures and Perioperative Managementmentioning

confidence: 99%

Peripheral Lymphocyte Subsets Absolute Counts as Feasible Clinical Markers for Predicting Surgical Outcome in Gastric Cancer Patients After Laparoscopic D2 Gastrectomy: A Prospective Cohort Study

Zeng¹,

Tong²,

Xiao³

et al. 2021

JIR

View full text Add to dashboard Cite

Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision

Abstract: Laparoscopic distal gastrectomy with complete mesogastric excision reduces the number of free intraperitoneal cancer cells and is associated with a better disease-free survival than conventional D2 gastrectomy.

Cited by 21 publications

References 28 publications

Correspondence

Correspondence

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Peripheral Lymphocyte Subsets Absolute Counts as Feasible Clinical Markers for Predicting Surgical Outcome in Gastric Cancer Patients After Laparoscopic D2 Gastrectomy: A Prospective Cohort Study

Contact Info

Product

Resources

About